First trial of RXR agonist
IRVINE, California-NuRx Pharmaceuticals, Inc. has dosed the first patient in a single-center phase I clinical trial of its first-in-class rexinoid receptor (RXR) agonist NRX4204.
IRVINE, California-NuRx Pharmaceuticals, Inc. has dosed the first patient in a single-center phase I clinical trial of its first-in-class rexinoid receptor (RXR) agonist NRX4204. In preclinical studies, the orally bioavailable RXR agonist was effective in models of non-small-cell lung cancer and breast cancer.
Articles in this issue
Immunotherapy agent promising in NSCLC
NCCN greenlights nilotinib for imatinib-resistant CML patients
No overall survival benefit for dose-intense regimen in SCLC
Make a note of new smoking cessation codes
Relistor for treating OIC
Experts argue against need for phase III proton Rx trials
Spotlight on Cancer Centers
Novel peptide vaccine promising in myeloid leukemia
Masters of hematology and oncology: Father of tamoxifen a Brit to the core
Intensive imatinib/chemo ups EFS in pediatric Ph+ ALL
Relapsing DLBCL patients respond to rituximab-based Rx
Who’s News
From the Editor
New compound inhibits Src family kinases
Are two binding sites better than one?
Recent Videos
Related Content
Elevating the Quality of Cancer Care via Cross-Department Collaboration
Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD
April 7th 2025Podcast
Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.
